Skip to main content

Table 3 Univariate analysis

From: Predictors of major infections in systemic lupus erythematosus

  Major infection (n = 83) No major infection (n = 166) P value
Female sex 73/83 (88) 150/166 (90) 0.70
Nephritis at study point 15/83 (18) 10/166 (6) <0.01
Previous nephritis 34/83 (41) 39/166 (23) <0.01
Thrombocytopenia at study point 6/83 (7) 7/166 (4) 0.50
Previous thrombocytopenia 19/83 (23) 27/166 (16) 0.27
Lung disease at study point 12/83 (14) 6/166 (4) <0.01
Previous lung disease 13/83 (15) 8/166 (5) <0.01
Leukopenia at study point 32/83 (39) 23/166 (14) <0.01
Low complement at study point 36/81 (44) 52/163 (32) 0.08
Anti-DNA antibodies 61/83 (73) 102/166 (61) 0.08
Antiphospholipid antibodies 43/83 (52) 57/166 (34) 0.01
SDI = 0 57/83 (69) 125/166 (75)  
SDI = 1 to 2 22/83 (26) 38/166 (23) 0.29
SDI >2 4/83 (5) 3/166 (2)  
SLEDAI at diagnosis 10 (1 to 25) 9 (1 to 22) 0.23
SLEDAI at study point 4 (0 to 24) 3 (0 to 21) 0.15
SLEDAI at diagnosis >12 25/81 (31) 33/163 (20) 0.09
SLEDAI at study point >12 5/81 (6) 7/163 (4) 0.74
Antimalarials 18/83 (22) 128/166 (77) <0.01
Months on antimalarials 0 (0 to 300) 24 (0 to 192) <0.01
Azathioprine 16/83 (19)a 20/166 (12) 0.18
Methotrexate 2/83 (3) 13/166 (8) 0.12
Cyclophosphamide 3/83 (4) 2/166 (1) 0.42
Mycophenolate 1/83 (1) 5/166 (3) 0.66
Cyclosporine 3/83 (2)a 4/166 (5) 0.34
Any immunosuppressor 23/83 (30) 44/166 (26) 0.96
Prednisone 62/83 (75) 90/166 (54) <0.01
Prednisone dose (mg/day) 7.5 (0 to 90) 2.5 (0 to 60) <0.01
  1. Data presented as n/N (%) or median (range). SDI, Systemic Lupus International Collaborating Clinics Damage Index; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index. aTwo patients were taking combined treatment with azathioprine and cyclosporine.